Instrumento Inactivo

Acciones Idenix Pharmaceuticals Inc

Acciones

Precio de cierre Nasdaq Otros sitios de cotización
- ^USD	-

AbbVie : Merck says hepatitis C drugs to lose breakthrough status	04/02/15
Idenix Pharmaceuticals : Merck dépasse les attentes malgré la concurrence des génériques	29/07/14
Apple : Wall St. edges up, lifted by mergers, acquisitions	10/06/14
Idenix Pharmaceuticals : Ryan & Maniskas, LLP : Announces Investigation of Idenix Pharmaceuticals Inc.	10/06/14
Apple : U.S. futures dip, S&P 500 comes off fourth straight record	10/06/14

Directores	Puesto	Edad	Desde
Teresa Dahlman IRC	Investor Relations Contact	-	-
Michele Liuzzi PRN	Corporate Officer/Principal	-	-
Adel Moussa PRN	Corporate Officer/Principal	-	01/03/02

Sector

	Varia. 1 de ene.	Capi.
CSL LIMITED	-3,99 %	87,17 mil M
SAMSUNG BIOLOGICS CO.,LTD.	+2,76 %	40,1 mil M
BIOGEN INC.	-16,98 %	31,38 mil M
UCB	+57,86 %	25,12 mil M
BIOMARIN PHARMACEUTICAL INC.	-16,24 %	15,59 mil M
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9,12 %	12 mil M
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42,56 %	11,8 mil M
INCYTE CORPORATION	-17,10 %	11,8 mil M
SWEDISH ORPHAN BIOVITRUM AB	+6,89 %	8813,5 M